To assess the safety and efficacy of antithrombotic therapy.
- Aspirin (acute stroke) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Heparin (acute stroke) Drug
Intervention Desc: Intravenous anticoagulant.
Randomized, open trial involving 19435 patients.
Half of the 19,435 participating patients received unfractionated heparin (5000 or 12,500 IU twice daily) and half were told to avoid heparin. In a factorial design, half received aspirin 300 mg daily and half were told to avoid aspirin. Treatment was continued for 14 days or until hospital discharge.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Death within 14 days and death or dependency at 6 months.|